Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting

Molecular-level features of tumours can be tracked using single-cell analyses of circulating tumour cells (CTCs). However, single-cell measurements of protein expression for rare CTCs are hampered by the presence of a large number of non-target cells. Here, we show that antibody-mediated labelling of intracellular proteins in the nucleus, mitochondria and cytoplasm of human cells with magnetic nanoparticles enables analysis of target proteins at the single-cell level by sorting the cells according to their nanoparticle content in a microfluidic device with cell-capture zones sandwiched between arrays of magnets. We used the magnetic labelling and cell-sorting approach to track the expression of therapeutic protein targets in CTCs isolated from blood samples of mice with orthotopic prostate xenografts and from patients with metastatic castration-resistant prostate cancer. We also show that mutated proteins that are drug targets or markers of therapeutic response can be directly identified in CTCs, analysed at the single-cell level and used to predict how mice with drug-susceptible and drug-resistant pancreatic tumour xenografts respond to therapy. The expression of therapeutic protein targets in circulating tumour cells isolated from blood samples of patients with cancer can be tracked at the single-cell level by antibody-mediated magnetic labelling and microfluidic sorting.

Automated summary

Researchers have developed a method for tracking the expression of therapeutic protein targets in circulating tumour cells at the single-cell level using antibody-mediated magnetic labelling and microfluidic sorting. This approach allows for the direct identification of mutated proteins in CTCs and prediction of treatment response in mice with drug-susceptible and drug-resistant tumour xenografts.